Baird believes the pipeline for Biomarin is undervalued ahead of catalyst rich 2024. The company is a commercial-stage biotechnology company specializing in the development and commercialization of novel therapeutics for rare diseases. Over the course of the next couple of quarters, Baird expects Ultragenyx to announce data updates from four of their key pipeline programs. Baird maintains its Outperform rating and $68 price target on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RARE:
- Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- JPMorgan ups Ultragenyx target, adds to Analyst Focus List
- Ultragenyx price target lowered to $124 from $131 at Stifel
- Mereo BioPharma provides update on pipeline progress, corporate developments
